Zymeworks Inc. (ZYME) Closes Theravance Deal, Guides 2026 Revenue $278M—$292M

Zymeworks closed its Theravance Biopharma acquisition, adding YUPELRI cash flows, and guided 2026 revenue to $278M—$292M and Adjusted EBITDA to $114M—$128M.Material DetailsContext by AI AnalystThis is a mid-cycle shift to a cash-flow-supported model via asset aggregation, following FDA approval of…